NATOLI, Claudio
 Distribuzione geografica
Continente #
NA - Nord America 303
EU - Europa 99
AS - Asia 50
SA - Sud America 3
AF - Africa 1
Totale 456
Nazione #
US - Stati Uniti d'America 300
IT - Italia 42
IN - India 17
DE - Germania 16
SE - Svezia 16
SG - Singapore 15
CN - Cina 12
GB - Regno Unito 5
UA - Ucraina 4
RU - Federazione Russa 3
AR - Argentina 2
BG - Bulgaria 2
CA - Canada 2
FI - Finlandia 2
HK - Hong Kong 2
HR - Croazia 2
JP - Giappone 2
PL - Polonia 2
BE - Belgio 1
BO - Bolivia 1
BT - Bhutan 1
CZ - Repubblica Ceca 1
ES - Italia 1
MX - Messico 1
NL - Olanda 1
RO - Romania 1
TG - Togo 1
TR - Turchia 1
Totale 456
Città #
Fairfield 46
Ashburn 36
Chandler 25
Houston 25
Seattle 24
Woodbridge 22
Wilmington 21
Cambridge 17
San Paolo di Civitate 11
Singapore 8
Princeton 7
Rome 7
Ann Arbor 6
Beijing 6
Lawrence 6
Millbury 5
Milan 4
Boston 3
Norwalk 3
Andover 2
Bremen 2
Bühl 2
Federal 2
Helsinki 2
Hong Kong 2
Jinan 2
Lublin 2
New York 2
Ottawa 2
San Diego 2
Sofia 2
Tokyo 2
White Plains 2
Zagreb 2
Brussels 1
Chicago 1
Chieti 1
Civitavecchia 1
Dolianova 1
Edinburgh 1
Guangzhou 1
Gunzenhausen 1
Hefei 1
Islington 1
Izmir 1
Jacksonville 1
Kunming 1
La Paz 1
Legnano 1
Lomé 1
Madrid 1
Marino 1
Mexico City 1
Nanjing 1
Phoenix 1
Prague 1
Redwood City 1
Sacramento 1
Santa Clara 1
Sassari 1
Southend 1
Thimphu 1
Totale 340
Nome #
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 118
INfluenza vaccine indication during therapy with Immune checkpoint inhibitors: a transversal challenge. the INVIDIa study 94
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab. a real-life multicentre study 75
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study 71
Immunotherapy in HER2-positive breast cancer. state of the art and future perspectives 55
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors. A multicentre analysis of immune-related adverse events 44
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. An Italian multicenter real life study 35
Totale 492
Categoria #
all - tutte 1.338
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.338


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020160 0 0 7 19 21 18 27 18 19 11 13 7
2020/202182 5 11 6 2 6 7 2 12 3 11 13 4
2021/202276 0 1 7 1 13 2 0 13 10 2 18 9
2022/2023114 16 22 4 13 11 6 2 15 13 0 5 7
2023/202443 2 4 1 10 5 5 2 2 2 6 4 0
2024/202517 2 5 10 0 0 0 0 0 0 0 0 0
Totale 492